Full Press Release Details
Therapeutics Receives $4 Million Through Warrant Exercises
Warrants exercised at $6 per share
cash runway through Q3 2023
Mass., March 25, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing
treatments for severe neurodegenerative diseases, today announced it has received proceeds of approximately $4 million from the
exercise of warrants priced at $6 per share. The warrants were issued as part of the Company's $12 million initial public offering (IPO)
that closed in December 2021.
cash runway extends through Q3 2023 and, importantly, beyond the expected completion of our upcoming Phase IIb study of our lead drug
candidate PrimeC in the treatment of amyotrophic lateral sclerosis (ALS), a major value-driving milestone," stated NeuroSense CEO
PrimeC Phase IIb Study
was granted Orphan Drug Designation by the US FDA and the European Medicines Agency (EMA). NeuroSense completed a Phase IIa clinical
study which successfully met its safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically
significant changes in ALS-related biological markers indicating PrimeC's biological activity. The Company plans to initiate a Phase
IIb double-blind placebo-controlled multinational study in Q2 2022 with an optimized dose and a unique upgraded formulation.
lateral sclerosis (ALS) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis.
Every year, more than 5,000 patients are diagnosed with ALS in the US alone, with an annual disease burden of $1 billion. The number
of patients with ALS is expected to grow 24% by 2040 in the US and EU.
Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering
from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS),
Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with
limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on
strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple
pathways associated with these diseases.
press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"
"could," "estimate," "expect," "intend," "seek," "may," "might,"
"plan," "potential," "predict," "project," "target," "aim," "should,"
"will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements
contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict and include statements regarding patent applications; the company's
PrimeC development program; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC;
the timing of current and future clinical trials; the nature, strategy and focus of the company and further updates with respect thereto;
and the development and commercial potential of any product candidates of the company. Further, certain forward-looking statements are
based on assumptions as to future events that may not prove to be accurate. Forward-looking statements contained in this announcement
are made as of this date, and NeuroSense Therapeutics Ltd. undertakes no duty to update such information except as required under applicable
